🧠AI AnalysisFDA Approves First New Advanced Head and Neck Cancer Treatment in a Decade
The U.S. Food and Drug Administration has granted accelerated approval to Rybrevant Faspro for adults with advanced head and neck squamous cell carcinoma.
🧠AI AnalysisThe U.S. Food and Drug Administration has granted accelerated approval to Rybrevant Faspro for adults with advanced head and neck squamous cell carcinoma.
Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.